India to Uzbekistan Pharmaceutical Export

The pharmaceutical trade corridor between India and Uzbekistan has experienced significant growth and development over the past decade. In 2024, India's pharmaceutical exports to Uzbekistan were valued at $108.68 million, marking a substantial increase from previous years. This surge can be attributed to India's expanding pharmaceutical manufacturing capabilities and Uzbekistan's growing demand for quality medicines. The establishment of a structured pharmaceutical and nutraceutical trade corridor in March 2026 further solidified this bilateral relationship, aiming to enhance regulatory alignment and market access for Indian manufacturers targeting the Eurasian market.

India holds a dominant position in Uzbekistan's pharmaceutical import market. In 2024, Uzbekistan's total pharmaceutical imports amounted to $843.17 million, with India accounting for approximately $569.53 million of this total. This substantial share underscores India's strategic importance as a key supplier of pharmaceutical products to Uzbekistan, catering to the country's increasing healthcare needs.

In March 2026, India and Uzbekistan launched a policy-backed pharmaceutical and nutraceutical trade corridor aimed at improving regulatory alignment, investment, and market access for manufacturers targeting the $7–10 billion Eurasian healthcare market. This initiative reflects a broader attempt to create a more structured corridor connecting India's manufacturing strength with consumer-health demand across Eurasia.

EXPORT_REGULATORY

Indian pharmaceutical companies seeking to register products in Uzbekistan must adhere to the country's regulatory requirements, which include compliance with Good Manufacturing Practice (GMP) standards. The registration process involves submitting a comprehensive dossier, typically in the Common Technical Document (CTD) format, to the Ministry of Health of Uzbekistan. This dossier must demonstrate the product's quality, safety, and efficacy. The registration timeline can vary, but it generally includes an evaluation period followed by an on-site inspection to verify compliance with GMP standards. Notably, as of January 1, 2023, the registration of new medicines requires positive outcomes from clinical trials and examination of manufacturing conditions for GMP compliance.

Uzbekistan mandates that pharmaceutical products imported into the country be manufactured in facilities that comply with GMP standards. The Ministry of Health conducts inspections to ensure that manufacturing sites meet these requirements. Compliance with GMP is essential for the registration and continued sale of pharmaceutical products in Uzbekistan. The Ministry of Health of Uzbekistan oversees the implementation of GMP regulations, ensuring that pharmaceutical products meet the necessary quality standards. (portfolio.afu.uz)

To import pharmaceutical products into Uzbekistan, Indian exporters must provide several key documents, including:

• Certificate of Pharmaceutical Product (CPP): Confirms that the product is authorized for sale in the exporting country.

• Certificate of Analysis (CoA): Provides detailed information on the product's composition and quality.

• GMP Certificate: Demonstrates that the manufacturing facility adheres to GMP standards.

These documents are essential for customs clearance and regulatory approval in Uzbekistan. Additionally, compliance with Uzbekistan's customs procedures is required for the importation of pharmaceutical products.

EXPORT_TRENDS

India's pharmaceutical exports to Uzbekistan are predominantly composed of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. These products align with Uzbekistan's healthcare needs, addressing a range of medical conditions prevalent in the country. The therapeutic areas that dominate exports include pain management, infectious diseases, and chronic conditions such as hypertension and diabetes. The demand for these products is driven by the increasing prevalence of these health issues and the need for accessible and effective treatments.

The launch of the pharmaceutical and nutraceutical trade corridor in March 2026 presents new opportunities for Indian exporters to introduce innovative products to the Uzbek market. There is a growing demand for biosimilars and generic drugs in Uzbekistan, particularly as patent protections for original drugs expire. Indian companies can leverage their expertise in these areas to meet the evolving needs of the Uzbek healthcare system.

Uzbekistan's increasing disease burden, aging population, and rising healthcare spending are significant drivers of pharmaceutical import demand. The country faces challenges with the prevalence of chronic diseases, infectious diseases, and a growing elderly population, all of which contribute to the heightened need for pharmaceutical products. Additionally, the government's efforts to improve healthcare infrastructure and access to medicines further stimulate demand for imported pharmaceuticals.

EXPORT_POLICY

Uzbekistan's tariff and duty structure for pharmaceutical formulations includes Most Favored Nation (MFN) tariff rates and preferential rates for certain products. While specific rates can vary, the government has implemented measures to encourage the import of essential medicines, including exemptions from Value Added Tax (VAT) for imported medicines not produced locally. These policies aim to make pharmaceuticals more accessible to the population.

Uzbekistan has engaged in bilateral trade agreements and initiatives to enhance pharmaceutical trade, including the establishment of the pharmaceutical and nutraceutical trade corridor with India in March 2026. This corridor aims to improve regulatory alignment, investment, and market access for manufacturers targeting the Eurasian healthcare market. Such agreements are expected to positively impact pharmaceutical trade by streamlining processes and fostering collaboration between the two countries.

Uzbekistan's intellectual property (IP) and patent landscape includes provisions for patent protection, data exclusivity, and compulsory licensing. These factors can influence the entry of Indian generic drugs into the Uzbek market. Understanding the nuances of Uzbekistan's IP laws is crucial for Indian exporters to navigate the market effectively and ensure compliance with local regulations.

EXPORT_LOGISTICS

Pharmaceutical products from India to Uzbekistan are primarily transported via sea and air routes. Sea shipments typically involve transit through major ports such as Mumbai and Chennai, with transit times varying based on the specific route and shipping conditions. Air shipments are routed through international airports, with transit times generally ranging from 5 to 7 days, depending on the specific origin and destination airports. It's important to monitor potential disruptions in key maritime routes, such as the Red Sea, which can impact shipping schedules and costs.

In India, key export ports for pharmaceutical products include Ahmedabad ICD (1.6%), Barhi ICD (0.2%), and Chennai Air (0.6%). In Uzbekistan, major import ports are Tashkent (19.1%), Tashkent (64.9%), and Poti (1.5%). These ports play a critical role in facilitating the efficient movement of pharmaceutical goods between the two countries.

Maintaining the integrity of pharmaceutical products during transit is essential, particularly for temperature-sensitive items. Implementing robust cold chain logistics, adhering to Good Distribution Practice (GDP) compliance, and ensuring appropriate packaging standards are critical to prevent product degradation and ensure patient safety. Both Indian exporters and Uzbek importers must collaborate to uphold these standards throughout the supply chain.

EXPORT_OPPORTUNITY

Uzbekistan's pharmaceutical market is experiencing growth, with imports reaching $843.17 million in 2024. The market is characterized by a significant share of generic drugs, reflecting the country's focus on cost-effective healthcare solutions. This growth presents opportunities for Indian pharmaceutical exporters to expand their presence and cater to the increasing demand for quality medicines.

Uzbekistan's healthcare system is undergoing reforms aimed at improving access to quality medicines and medical devices. The government has implemented measures to encourage the import of essential medicines, including exemptions from VAT for imported medicines not produced locally. These initiatives are designed to enhance the availability of pharmaceuticals and improve healthcare outcomes for the population.

The launch of the pharmaceutical and nutraceutical trade corridor in March 2026 provides Indian exporters with a structured platform to access the Eurasian market. This initiative facilitates regulatory alignment, investment, and market entry, creating opportunities for Indian companies to introduce innovative products and expand their market share in Uzbekistan and the broader Eurasian region.

EXPORT_COMPETITIVE

Uzbekistan's pharmaceutical import market is diverse, with suppliers from various countries, including China, the European